Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
Go back to Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 32.71 -0.97 (2.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.68 | 52 Week High | $5.17 | |||
| Open | $33.36 | 52 Week Low | $0.94 | |||
| Day High | $34.60 | P/E | N/A | |||
| Day Low | $32.68 | EPS | $0.00 | |||
| Volume | 999,321 | |||||
